Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMINI-2: Long-Term Extension Study of Imsidolimab in Generalized Pustular Psoriasis
NCT05366855Phase 3Terminated
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- Apr 2022
- Primary completion
- Jul 2024
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial of imsidolimab in generalized pustular psoriasis (GPP) (8 arms), sponsored by Vanda Pharmaceuticals Inc. Primary endpoint: Incidence of Adverse Events at Week 116. Started Apr 2022; status: terminated.
02
Drugs
imsidolimab
03
Conditions
generalized pustular psoriasis (GPP)
Beyond the preview
Go deeper on NCT05366855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05366855.